High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer

Lee, Hyun Woo; Hwang, Youn‐Ho; Han, Jae Ho; Choi, Jin-Hyuk; Kang, Seok Yun; Jeong, Seong Hyun; Ann, Mi Sun; Oh, Young Taek; Kim, Jang-Hee; Kim, Chul Ho; Sheen, Seung Soo

doi:10.1016/j.oraloncology.2009.12.007

Cited by 29 publications

(30 citation statements)

References 27 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Secondly, wide heterogeneity of detection methods has been reported in studies under consideration [11][12][13][14][15][22][23][24][25][26][27][28][29][30][31][32][33]. It has been shown that ERCC1 immunodetection faces several methodological challenges including tissue processing, rates of interobserver agreement, geographic variation in protein expression and, most importantly, lack of the standardized cutoff value in semi-quantitative IHC [39][40][41].…”

Section: Discussionmentioning

confidence: 99%

“…ERCC1 expression stratified by human papillomavirus (HPV) status in head and neck cancers. At the end, 17 studies containing 1288 patients were included in metaanalysis [11][12][13][14][15][22][23][24][25][26][27][28][29][30][31][32][33].…”

Section: Eligible Studiesmentioning

confidence: 99%

“…Studies were published between 2007 and 2014 and sample sizes of datasets ranged from 26 to 176. Nine studies were conducted in Caucasian patients [13-15, 23-25, 27-28, 30], seven studies in Asian patients [22,26,[28][29][32][33] and one in South American patients [11].…”

Section: Eligible Studiesmentioning

confidence: 99%

“…The covariates reported in included studies were: age and TNM stage in all studies, site [11-13, 15, 25], sex [11,22,26,30], tumor differentiation [11,13,25,30], performance status [28,30], histologic type [29,33], smoking [15,22], alcohol drinking [22], betel nuts chewing [22], HPV status [15], treatment methods [28,33], resection margin [11], extracapsular spreading [11], previous RT [30], relapse interval [30] and phosphor-mTOR expression [28]. The 6 pooled analysis showed that high ERCC1 expression was associated with shorter OS (HR = 1.95, 95% CI = 1.18 -3.21, I 2 = 70.8%, p = 0.000 for heterogeneity) ( Fig.…”

Section: Overall Survivalmentioning

confidence: 99%

“…Six studies were performed in Asians containing 357 patients [12,22,26,[29][30]32], while four studies were conducted in Caucasians containing 230 patients [13,[23][24][25]. Low ERCC1 was associated with better ORR in Asian patients (OR = 0.29, 95% CI = 0.17 -0.52; I 2 = 31.7) while there was no association between ERCC1 expression and response to chemotherapy containing treatment in Caucasian patients (OR = 0.81, 95% CI = 0.40 -1.67; I 2 = 65.3 %) ( Table 2 and Fig.…”

mentioning

confidence: 99%

See 4 more Smart Citations

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

Bišof

Petranović

Rakušić

et al. 2015

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Eligible Studiesmentioning

confidence: 99%

Section: Eligible Studiesmentioning

confidence: 99%

Section: Overall Survivalmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

Bišof

Petranović

Rakušić

et al. 2015

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

Clinical utility of plasma Epstein‐Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma

Hui

B.Y.

Chan

et al. 2015

Cancer

View full text Add to dashboard Cite

BACKGROUND: Single nucleotide polymorphism (SNP) of the excision repair cross-complementing group 1 (ERCC1) gene has been linked with sensitivity to platinum and radiation. The authors hypothesized that the ERCC1 genotype for the SNPs cytosine-tothymine substitution at codon 118 (C118T) and cytosine-to-adenine substitution at codon 8092 (C8092A) is prognostic in patients with nasopharyngeal carcinoma (NPC) who receive either radiotherapy (RT) or cisplatin plus RT. METHODS: The authors tested their hypothesis using biomarker screening samples from the Hong Kong NPC Study Group 0502 trial, which was a prospective, multicenter clinical trial that used post-RT plasma Epstein-Bar virus (EBV) DNA (pEBV) levels to screen patients with high-risk NPC for adjuvant chemotherapy. RESULTS: ERCC1 SNPs were analyzed in 576 consecutive patients who were screened by pEBV. In the total biomarker population, there was no significant association of ERCC1 C118T or C8092A genotype with relapse-free survival (RFS) or overall survival (OS). There also was no correlation between ERCC1 genotype and ERCC1 protein or messenger RNA expression in a subset of patients who had available paired biopsies. Post-RT pEBV status was the only independent prognosticator for RFS and OS in multivariate analyses. However, there was a significant interaction between ERCC1 C118T genotype and post-RT pEBV status (RFS, P 5.0106; OS, P 5.0067). The ERCC1 C118T genotype was significantly associated with both RFS (hazard ratio, 1.67; 95% confidence interval, 1.07-2.61; P 5.024) and OS (hazard ratio, 2.31; 95% confidence interval, 1.22-4.40; P 5.0106) in the post-RT pEBV-negative population, but not in the pEBV-positive population. CONCLUSIONS: The current results prospectively validate pEBV as the most significant prognostic biomarker in NPC that can be used to select high-risk patients for adjuvant therapy. The ERCC1 C118T genotype may help to identify a favorable subgroup (approximately 7%) of pEBV-negative patients with NPC who have an excellent prognosis and can be spared the toxicities of further therapy. Cancer 2015;121:2720-9.

show abstract

Role of excision repair cross‐complementation 1 expression as a prognostic marker for response to radiotherapy in early‐stage laryngeal cancer

Johung

Rewari²,

et al. 2012

Head & Neck

View full text Add to dashboard Cite

Background and Purpose Tumors with high expression of excision repair cross complementation 1 (ERCC1) are resistant to platinum-based chemotherapy or chemoradiotherapy. We evaluated the prognostic value of ERCC1 expression in a cohort of laryngeal cancer treated with radiotherapy alone, to determine if expression correlated with clinicopathologic risk factors, local control, or overall survival. Material and Methods The study included 123 patients with stages I – II laryngeal squamous cell carcinoma treated to a median dose of 66 Gy using standard fields and fractionation. ERCC1 expression was examined by immunohistochemical analysis of tissue microarrays. Results ERCC1 expression did not correlate with standard prognostic factors, local control, or overall survival. At 5 years, local control was 75% vs. 71% (p = 0.78) and overall survival was 68% vs. 54% (p = 0.65), for non-expressors and expressors of ERCC1, respectively. Multivariate analysis identified T stage as the only independent predictor for local control, and T stage and age as predictors for overall survival. Conclusions ERCC1 expression did not predict for radiotherapy resistance or worse survival in these laryngeal cancer patients. Though ERCC1 is a marker of resistance to platinum-based chemotherapy and chemoradiation, radiotherapy remains an effective treatment in tumors with high ERCC1 expression.

show abstract

High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer

Cited by 29 publications

References 27 publications

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis

Clinical utility of plasma Epstein‐Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma

Role of excision repair cross‐complementation 1 expression as a prognostic marker for response to radiotherapy in early‐stage laryngeal cancer

Contact Info

Product

Resources

About